PTPA and neoplasm: In turn, CIP-2a promotes tumorigenesis and, in general, tumor progression by inhibiting the activity of protein phosphatase 2A (PP2A)—a prerequisite for the oncogenic transformation of human cells—and by stabilizing c-MYC in different tumors.